The world’s first malaria vaccine, produced by GlaxoSmithKline, could be approved by international regulators for use in Africa from October.
Then, it showed it only reduced episodes of malaria in babies aged six weeks to 12 weeks by 27 per cent, and by around 46 per cent in children aged five to 17 months.
But the final stage follow-up data published in the Lancet journal showed that vaccinated children continued to be protected four years on, though at a declining rate – an important factor, given the prevalence of the disease and rates of protection were stronger with a booster shot.
“In spite of the falling efficacy over time, there is still a clear benefit from RTS,S,” said Brian Greenwood, a professor at the London School of Hygiene & Tropical Medicine who worked on the study.
“The children would normally be expected to have had several cases of infection over that period.
“Given that there were an estimated 198 million malaria cases in 2013, this level of efficacy potentially translates into millions of cases of malaria in children being prevented,” Greenwood said.
GSK submitted an application in July 2014 for regulatory approval by the European Medicines Agency for RTS, S and is expecting a decision within a few months.
“If it gets a licence, the World Health Organisation could recommend it for use “as early as October this year,”Greenwood said.
Experts say RTS, S will be only one among several weapons against malaria, alongside insecticide-treated bed nets, rapid diagnostic tests and anti-malarial drugs.